Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis (NVS) stock slips despite better than expected Q3 results amid concerns over a cancer drug added with its $3B ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...